ALPROLIX® is the only factor IX to utilize half-life extension with Fc Fusion technology
The natural recycling pathway of IgG1 allows ALPROLIX to stay in the body for an extended period of time between infusions1
*A subset of 22 patients (the sequential pharmacokinetic subgroup) received consecutive single IV doses of 50 IU/kg BeneFIX and ALPROLIX at the beginning of the B-LONG study (baseline) for direct comparison. For both ALPROLIX and BeneFIX, peak activity was reached approximately 10 minutes after the start of the infusion.3
†Peak activity level does not mean bleeds are resolved within 10 minutes.
BeneFIX® is a registered trademark of Pfizer Inc.
rFIX=recombinant factor IX.